Abstract
Introduction
Changes in drug treatment are frequently mandatory with hospital admission and discharge because hospital drug formularies are generally restricted to about 3000 drugs as compared to the many times this number – 62,000 in Germany – that are commercially available. Without computerised support, the process involved with switching drugs to a corresponding generic or a therapeutic equivalent is time-consuming and error-prone.
Methods
We have developed and tested a standardised interchange algorithm for subsequent implementation into a computerised decision support system that switches drugs to the corresponding generic or a therapeutic equivalent if they are not listed on the hospital drug formulary.
Results
The algorithm was retrospectively applied to the medication regimens of 120 patients (774 prescribed drugs containing 886 active ingredients) at their time of admission to surgical wards. Of the prescribed drugs, 52.8% (409/774) were part of the hospital drug formulary, thereby rendering a switch unnecessary. The 365 drugs not listed consisted of 392 active ingredients that were successfully switched to a corresponding generic (84.7%) or a therapeutic equivalent (10.2%). No specific switching procedures were defined for only 2.3% (20/886) of the active ingredients. In these cases, the drugs were either discontinued (4/20) or special drug classes, current diseases or co-medication required manual switching (8/20), or the drugs were continued unchanged and ordered from a wholesaler (8/20).
Conclusion
Using a standardised interchange algorithm, pre-admission drug regimens can successfully be switched to drugs on a hospital drug formulary. These findings suggest that a computerised decision support system will likely be useful to support this important practice.
Similar content being viewed by others
References
Himmel W, Tabache M, Kochen MM (1996) What happens to long-term medication when general practice patients are referred to hospital? Eur J Clin Pharmacol 50:253–257
Cornish PL, Knowles SR, Marchesano R, Tam V, Shadowitz S, Juurlink DN, Etchells EE (2005) Unintended medication discrepancies at the time of hospital admission. Arch Intern Med 165:424–429
Himmel W, Kochen MM, Sorns U, Hummers-Pradier E (2004) Drug changes at the interface between primary and secondary care. Int J Clin Pharmacol Ther 42:103–109
Forster AJ, Murff HJ, Peterson JF, Gandhi TK, Bates DW (2003) The incidence and severity of adverse events affecting patients after discharge from the hospital. Ann Intern Med 138:161–167
Summers KH, Szeinbach SL (1993) Formularies: the role of pharmacy-and-therapeutics (P&T) committees. Clin Ther 15:433–441; discussion 432
Thuermann PA, Harder S, Steioff A (1997) Structure and activities of hospital drug committees in Germany. Eur J Clin Pharmacol 52:429–435
de Smedt M (1994) Drug formularies—good or evil? A view from the EEC. Cardiology 85[Suppl 1]:41–45
Himmel W, Lonker B, Kochen MM (1998) Nonformulary drug requests at an academic hospital in Germany—the role of general practitioners’ long-term medication. Eur J Clin Pharmacol 54:41–46
Massoomi F (1996) Formulary management: antibiotics and therapeutic interchange. Pharm Pract Manag Q 16:11–18
Schachtner JM, Guharoy R, Medicis JJ, Newman N, Speizer R (2002) Prevalence and cost savings of therapeutic interchange among U.S. hospitals. Am J Health Syst Pharm 59:529–533
Navarro de Lara S, Font Noguera I, Lerma Gaude V, Lopez Briz E, Martinez Pascual MJ, Poveda Andres JL (2004) Therapeutic interchange of drugs not included in the hospitals pharmacotherapeutic guide: a quality program. Farm Hosp 28:266–274
The European Agency for the Evaluation of Medicinal Products (2001) Note for guidance on the investigation of bioavailability and bioeqivalence. CPMP/EWP/QWP/1401/98. Available at: http://www.emea.ei.int/pdfs/human/ewp/140198en.pdf. Accessed March 20, 2007
Gray T, Bertch K, Galt K, Gonyeau M, Karpiuk E, Oyen L, Sudekum MJ, Vermeulen LC (2005) Guidelines for therapeutic interchange—2004. Pharmacotherapy 25:1666–1680
Grace KA, Swiecki J, Hyatt R, Gibbs H, Jones DL, Sheikh M, Spain J, Maneval KW, Viola R, Taylor AJ (2002) Implementation of a therapeutic-interchange clinic for HMG-CoA reductase inhibitors. Am J Health Syst Pharm 59:1077–1082
Stoysich A, Massoomi F (2002) Automatic interchange of the ACE inhibitors: decision-making process and initial results. Formulary 37:41–44
Porta Oltra B, Borras Almenar C, Jimenez Torres NV (2005) Therapeutic interchange standardization for antiotensin II receptor antagonists in the treatment of hypertension in the hospital setting. Farm Hosp 29:104–112
Teich JM, Merchia PR, Schmiz JL, Kuperman GJ, Spurr CD, Bates DW (2000) Effects of computerized physician order entry on prescribing practices. Arch Intern Med 160:2741–2747
Manolakis PG (2007) Prescription drug product substitution decision support. J Am Pharm Assoc (2003) 47:328–338
Sabatini S, Ferguson RM, Helderman JH, Hull AR, Kirkpatrick BS, Barr WH (1999) Drug substitution in transplantation: a National Kidney Foundation White Paper. Am J Kidney Dis 33:389–397
Wall DS, Abel SR (1996) Therapeutic-interchange algorithm for multiple drug classes. Am J Health Syst Pharm 53:1295–1296
Kaltschmidt J, Gallin S, Haefeli WE (2004) Essential functional requirements for an effective electronic drug information system in a hospital (abstract). Int J Clin Pharmacol Ther 42:615
WHO Collaborating Centre for drug Statistics Methology (2002) ATC Index with DDDs. WHO Collaborating Centre, Oslo
Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383
Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, Saunders LD, Beck CA, Feasby TE, Ghali WA (2005) Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 43:1130–1139
Straka RJ, Swanson AL, Parra D (1998) Calcium channel antagonists: morbidity and mortality—what’s the evidence? Am Fam Physician 57:1551–1560
Burnier M, Brunner HR (2000) Angiotensin II receptor antagonists. Lancet 355:637–645
Menz W (2006) AABG: Preisgünstige Therapiealternativen nach §115 SGB V. Insuline. Krankenhauspharmazie 27:93–102. Available at: http://krankenhauspharmazie.de/AABG/KPH-aabg.HTM
Furberg CD, Pitt B (2001) Are all angiotensin-converting enzyme inhibitors interchangeable? J Am Coll Cardiol 37:1456–1460
Djavan B, Marberger M (1999) A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 36:1–13
Fibbe C, Keller J, Layer P (2005) Short practice guideline for the management of gastroesophageal reflux disease. Dtsch Med Wochenschr 130:1970–1973
Maron DJ, Fazio S, Linton MF (2000) Current perspectives on statins. Circulation 101:207–213
Tam VC, Knowles SR, Cornish PL, Fine N, Marchesano R, Etchells EE (2005) Frequency, type and clinical importance of medication history errors at admission to hospital: a systematic review. Can Med Assoc J 173:510–515
Fijn R, Lenderink AW, Egberts AC, Brouwers JR, De Jong-Van DenBerg LT (2001) Assessment of indicators for hospital drug formulary non-adherence. Eur J Clin Pharmacol 57:677–684
Eckdaten der Krankenhausstatistik 2004/2005. Available at: http://www.dkgev.de/dkgev.php/cat/143/title/Eckdaten+Krankenhausstatistik+2005. Accessed May 2, 2007
Abourjaily P, Gouveia WA, Selker HP, Zucker DR (2005) Evaluating the nondrug costs of formulary coverage restrictions. Manag Care 14:50–57
Furberg CD, Herrington DM, Psaty BM (1999) Are drugs within a class interchangeable? Lancet 354:1202–1204
Furberg CD, Psaty BM, Herrington DM (2000) Are drugs interchangeable? Lancet 355:317–318
Kereiakes DJ, Willerson JT (2003) Therapeutic substitution: guilty until proven innocent. Circulation 108:2611–2612
Bergk V, Gasse C, Rothenbacher D, Loew M, Brenner H, Haefeli WE (2004) Drug interactions in primary care: impact of a new algorithm on risk determination. Clin Pharmacol Ther 76:85–96
Chong PH (2002) Lack of therapeutic interchangeability of HMG-CoA reductase inhibitors. Ann Pharmacother 36:1907–1917
Schwabe U (2007) Arzneiverordnungen 2005 im Ueberblick. In: Schwabe U, Paffrath D (eds) Arzneiverordnungsreport 2006. Springer Medizin, Heidelberg, pp 3–46
Meredith P (2003) Bioequivalence and other unresolved issues in generic drug substitution. Clin Ther 25:2875–2890
Fattinger K, Roos M, Vergeres P, Holenstein C, Kind B, Masche U, Stocker DN, Braunschweig S, Kullak-Ublick GA, Galeazzi RL, Follath F, Gasser T, Meier PJ (2000) Epidemiology of drug exposure and adverse drug reactions in two swiss departments of internal medicine. Br J Clin Pharmacol 49:158–167
Laroche ML, Charmes JP, Nouaille Y, Fourrier A, Merle L (2006) Impact of hospitalisation in an acute medical geriatric unit on potentially inappropriate medication use. Drugs Aging 23:49–59
Conroy S, Choonara I, Impicciatore P, Mohn A, Arnell H, Rane A, Knoeppel C, Seyberth H, Pandolfini C, Raffaelli MP, Rocchi F, Bonati M, Jong G, de Hoog M, van den Anker J (2000) Survey of unlicensed and off label drug use in paediatric wards in European countries. European Network for Drug Investigation in Children. Br Med J 320:79–82
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Walk, S.U., Bertsche, T., Kaltschmidt, J. et al. Rule-based standardised switching of drugs at the interface between primary and tertiary care. Eur J Clin Pharmacol 64, 319–327 (2008). https://doi.org/10.1007/s00228-007-0402-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-007-0402-5